News for Ocugen, Inc. (OCGN)

Ocugen (OCGN) has announced significant changes to its Retina Scientific Advisory Board and Executive Leadership Team. The company has made these strategic move

MALVERN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced updates to its Retina Scientific Advisory Board (SAB) and Executive Leadership Team to enhance external guidance from key opinion leaders and strengthen the Company’s internal expertise in critical functions and as it pursues its goal of three BLAs in the next three years.

MALVERN, Pa., July 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) ( OCGN), a pioneering biotechnology leader in gene therapies for blindnes

Ocugen (OCGN) has dosed its first patient in the Phase 2/3 GARDian3 trial for the OCU410ST gene therapy targeting Stargardt disease. The trial will enro

Ocugen (OCGN) to announce Q2 2025 financial results on August 1, 2025, before market open. Earnings call scheduled for 8:30 a.m. ET on the same day, acc

MALVERN, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company’s second quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Friday, August 1, 2025.

Carisma Therapeutics (CARM) and OrthoCellix, a wholly-owned subsidiary of Ocugen (OCGN), announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the development of OrthoCellix’s NeoCart technology for the treatment of knee articular cartilage defects and plans to initiate a U.S. Food and Drug Administration-endorsed Phase 3 clinical trial for NeoCart. OrthoCellix is developing NeoCart as an autol

Carisma Therapeutics (CARM) has entered into a definitive merger agreement with OrthoCellix, a subsidiary of Ocugen, to combine the companies in an all-stock tr

Carisma Therapeutics and OrthoCellix have agreed to a definitive merger to form a Nasdaq-listed company focused on regenerative cell therapies for orthoped

Ocugen has a valuable IP portfolio, which should give it funding options. OCGN’s cash runway remains the main risk. Check out what makes OCGN worth a Buy.

Ocugen's gene therapy OCU410ST for Stargardt disease is gaining momentum after FDA approval for its phase 2/3 trial. Analyst projections suggest substan

Ocugen (OCGN) receives FDA clearance for Phase 2/3 trial of OCU410ST for Stargardt disease. Phase 1 showed 48% slower lesion growth and significant visu

**media[651626]**

**media[646566]**

Ocugen's (OCGN) gene therapy OCU410ST gains rare pediatric disease designation from the FDA, paving the way for expedited reviews. Analyst predictions s

H.C. Wainwright has adjusted its price target for Ocugen (OCGN), reducing it from $8 to $7, but maintained a Buy rating on the stock. This decision follows the

On May 12, 2025, HC Wainwright & Co., through its analyst Swayampakula Ramakanth, reaffirmed a 'Buy' rating for Ocugen (OCGN). The firm has chosen to maintain i

Ocugen (OCGN), a biopharmaceutical company, has maintained its "Buy" rating from Chardan Capital as of May 12, 2025. This consistent rating reflects the continu

Release Date: May 09, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Ocugen Inc (OCGN)